TCR beta sequencing in LMP2-positive and LMP2-negative human T cells treated with anti-PD-L1 and anti-TIM3 antibodies.

We report the change in TCR beta profile of LMP2 multimer-positive and multimer-negative human T cells generated following weekly stimulations with antigen-pulsed dendritic cells and subjected or not to PD-L1/TIM3 double blockade. Overall design: TCR beta (CDR3 region) at day 21 and 28 in LMP2 multimer FACS-sorted negative and positive fractions of human T cells cultured with or without anti-PD-L1 and anti-TIM3 antibodies from 4 healthy donors.